Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases | Corporate - EQS News

Andera Partners co-leads a 40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases Proceeds will enable the development of the Companys lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg-targeting candidates Financing co-led by Andera, Fountain Healthcare Partners and Forbion with support from all existing investors Bernard Coulie appointed as Independent Chairman with immediate effect PARIS, FRANCE MAY 15, 2023 Andera Partners co-leads a 40 million Series A financing of Dualyx NV, a Ghent, Belgium based biotech developing next generation immune modulators. Alongside Andera, Fountain Healthcare Partners and Forbion co-led the round, with support from existing investors V-Bio Ventures, BGV, PMV, VIB, HTGF, and GFF. The financing reflects the strategy of BioDiscovery 6 fund managed by Andera Partners, with investment into a highly innovative company developing novel drug candidates that can address significant unmet needs of patients suffering from autoimmune disorders. I am confident that the combined support of our new board will enable progress with our highly promising TNFR2 program, and ultimately our goal of addressing hard-to-treat autoimmune diseases, added Wouter Verhoeven, CEO of Dualyx. Responsible and committed, the management company regularly forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming.